22157.jpg
Global Head & Neck Cancer Drugs Market Research Report (2021 to 2026) - by Drug Class, Product, End-user and Region
05 janv. 2022 06h33 HE | Research and Markets
Dublin, Jan. 05, 2022 (GLOBE NEWSWIRE) -- The "Head & Neck Cancer Drugs Market Research Report by Drug Class, Product, End-user, and Region - Global Forecast to 2026 - Cumulative Impact of...
22157.jpg
RAS Targeting Therapies Market, 2031
09 nov. 2021 06h03 HE | Research and Markets
Dublin, Nov. 09, 2021 (GLOBE NEWSWIRE) -- The "RAS Targeting Therapies by Target Indication, Type of Molecule, Type of Therapy, and Route of Administration, Key Geographical Regions: Industry Trends...
BEI_ONC_4C_FlatLogo_Horizontal.jpg
BeiGene Reports Second Quarter 2020 Financial Results
06 août 2020 16h05 HE | BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, Aug. 06, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing...
BEI_ONC_4C_FlatLogo_Horizontal.jpg
BeiGene Announces Acceptance of a New Drug Application of Pamiparib in Ovarian Cancer in China
17 juil. 2020 09h00 HE | BeiGene, LTD.
BEIJING, China and CAMBRIDGE, Mass., July 17, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing...
BEI_ONC_4C_FlatLogo_Horizontal.jpg
BeiGene Announces Closing of Approximately $2.08 Billion Registered Direct Offering
15 juil. 2020 17h00 HE | BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, July 15, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing...
BEI_ONC_4C_FlatLogo_Horizontal.jpg
BeiGene Announces Pricing of Approximately $2.08 Billion Registered Direct Offering
12 juil. 2020 20h00 HE | BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, July 12, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing...
BEI_ONC_4C_FlatLogo_Horizontal.jpg
BeiGene to Host Investor Conference Call and Webcast to Discuss the Company’s Early Development Pipeline and Research
02 juil. 2020 07h00 HE | BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, July 02, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing...
BEI_ONC_4C_FlatLogo_Horizontal.jpg
BeiGene Announces Acceptance of a Supplemental New Drug Application for Tislelizumab in Combination with Chemotherapy in First-Line Advanced Non-Squamous Non-Small Cell Lung Cancer in China
19 juin 2020 00h27 HE | BeiGene, LTD.
BEIJING, China and CAMBRIDGE, Mass., June 19, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing...
BEI_ONC_4C_FlatLogo_Horizontal.jpg
BeiGene Announces European Medicines Agency Acceptance of its Marketing Authorization Application for BRUKINSA® (Zanubrutinib) for the Treatment of Patients with Waldenström’s Macroglobulinemia
18 juin 2020 07h30 HE | BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, June 18, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing...
BEI_ONC_4C_FlatLogo_Horizontal.jpg
BeiGene Announces the Approval of BRUKINSA™ (Zanubrutinib) in China for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma and Relapsed/Refractory Mantle Cell Lymphoma
03 juin 2020 07h15 HE | BeiGene, LTD.
BEIJING, China and CAMBRIDGE, Mass., June 03, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing...